Can you take Afamitresgene autoleucel with Rsv vaccine, pref a-pref b, recombinant?
1 drug interaction and 5 additional warnings found for the following 2 drugs:
- afamitresgene autoleucel
- rsv vaccine, pref a-pref b, recombinant
Drug interactions
Moderate drug interactions
Moderate:
RSV vaccine, preF A-preF B, recombinant afamitresgene autoleucel
Applies to: rsv vaccine, pref a-pref b, recombinant and afamitresgene autoleucel
If you are currently being treated or have recently been treated with afamitresgene autoleucel, you should let your doctor know before receiving RSV vaccine, preF A-preF B, recombinant. Depending on the dose and length of time you have been on afamitresgene autoleucel, you may have a reduced response to the vaccine. In some situations, your doctor may want to delay vaccination to give your body time to recover from the effects of afamitresgene autoleucel therapy. If you have recently been vaccinated with RSV vaccine, preF A-preF B, recombinant, your doctor may choose to postpone treatment with afamitresgene autoleucel for a couple of weeks or more. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
5 potential interactions Applies to: 5 conditions, including Syncope, Liver Disease, Infection, Immunodeficiency, and Renal Dysfunction.
Immunodeficiency
Moderate:
rsv vaccine, pref a-pref b, recombinant
RSV vaccine, preF A-preF B, recombinant has a moderate potential interaction with Immunodeficiency.
Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to the RSV vaccine.
Infection
Moderate:
afamitresgene autoleucel
Afamitresgene autoleucel has a moderate potential interaction with Infection.
Afamitresgene autoleucel is not recommended in patients with active infections. Additionally, this drug may cause viral reactivation. Patients should be screened for presence of viral and infectious agents (e.g., Epstein-Barr Virus, Cytomegalovirus, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus) if clinically indicated. Monitor for signs and symptoms of infection before and after treatment. Consider antiviral therapy to prevent viral reactivation per local guidelines.
Liver Disease
Moderate:
afamitresgene autoleucel
Afamitresgene autoleucel has a moderate potential interaction with Liver Disease.
Afamitresgene autoleucel has not been studied in patients with any degree of hepatic impairment.
Renal Dysfunction
Moderate:
afamitresgene autoleucel
Afamitresgene autoleucel has a moderate potential interaction with Renal Dysfunction.
Afamitresgene autoleucel has not been studied in patients with any degree of renal impairment.
Syncope
Moderate:
rsv vaccine, pref a-pref b, recombinant
RSV vaccine, preF A-preF B, recombinant has a moderate potential interaction with Syncope.
Syncope may occur in association with administration of injectable vaccines, including the RSV vaccine. Procedures should be in place to avoid injury from fainting, especially for patients who have previously fainted in association with an injection.
Report options
More resources
afamitresgene autoleucel
A total of 200 drugs are known to interact with afamitresgene autoleucel.
- Afamitresgene autoleucel is in the drug class miscellaneous antineoplastic cell and gene therapies.
- Afamitresgene autoleucel is used to treat Synovial Sarcoma.
rsv vaccine, pref a-pref b, recombinant
A total of 341 drugs are known to interact with rsv vaccine, pref a-pref b, recombinant.
- Rsv vaccine, pref a-pref b, recombinant is in the drug class viral vaccines.
- Rsv vaccine, pref a-pref b, recombinant is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.